AR and urogenital neoplasm: Although MYC activity is a well-known driver of prostate tumorigenesis, its relationship with individual genes and molecular processes remains actively investigated, with current efforts focusing on identifying effector genes or co-factors necessary for its positive association with androgen receptor (AR) activity [7, 10].